

Liebe Kolleginnen und Kollegen,

die Innovationen in unserem Fachgebiet haben zu wesentlichen Neuentwicklungen in Diagnostik und Therapie der hämatologischen und onkologischen Erkrankungen geführt und tragen maßgeblich zur Prognoseverbesserung unserer Patienten bei. Hierbei spielt der wissenschaftliche Austausch zwischen Arbeitsgruppen, Universitäten und akademischen Institutionen eine zentrale Rolle. In der neu eingerichteten Vorlesungsreihe „Harvard meets UKE“ möchten wir diesen Austausch stärken und freuen uns, gleich drei internationale Experten aus der Harvard Medical School bei uns am UKE begrüßen zu dürfen. Wir glauben, dass es auch für die in der Versorgung engagierten Kollegen und Partner des UCCH eine tolle Chance ist, international führende Wissenschaftler und Ihre Mitarbeiter „life“ zu erleben.

Zu Beginn dieser Reihe haben wir drei hämatologische Themen ausgewählt: Paul Richardson, Jennifer Brown und David Steensma, die in ihren jeweiligen wissenschaftlichen Schwerpunkten derzeitige Entwicklungen in führender Rolle mitgestaltet haben, werden über die neuen Erkenntnisse beim Multiplen Myelom, der chronisch lymphatischen Leukämie und der klonalen Hämatopoese bzw. den akuten Leukämien berichten.

Wir möchten Sie sehr herzlich zu dieser Vorlesungsreihe einladen. Wir sind uns sicher, dass wir drei sehr bereichernde Nachmittage erleben werden und freuen uns schon jetzt auf Ihr Kommen!

Mit kollegialen Grüßen

Prof. Dr. Carsten Bokemeyer


Prof. Dr. Katja Weisel

Kontakt / Anfahrt

Hubertus Wald Tumorzentrum
Universitäres Cancer Center Hamburg (UCCH)

Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg

Kontakt für Rückfragen:
W. Kobbe (w.kobbe@uke.de)



Hörsaal Fritz-Schumacher-Haus (N30)

Herzlichen Dank an die Unterstützer der Veranstaltung:



Höhe des Sponsorings: * 7.500; ** 5.000€; *** 3.000€



Seminar Series hosted by the UCCH Harvard meets UKE

Paradigm changes in Hematology
Myeloma-CLL-Hematopoiesis

26.03.2020 | 16.04.2020 | 30.04.2020



Universitätsklinikum Hamburg-Eppendorf

Program

26.03.2020 | 17:00 Uhr

Welcome by the UCCH Director
Prof. Dr. Carsten Bokemeyer

Introduction into the lecture series by the Dean
Prof. Dr. Dr. Uwe Koch-Gromus

„The Evolving Role of Novel and Next Generation Therapy in the Management of Newly Diagnosed Multiple Myeloma and Beyond: Current Status and Future Directions“

Paul Richardson, MD

Host: Prof. Dr. Katja Weisel

16.04.2020 | 17:00 Uhr

„The Changing Face of CLL Therapy“

Jennifer R. Brown, MD PhD

Host: PD Dr. Maximilian Christopeit

30.04.2020 | 17:00 Uhr

„Clinical implications of clonal hematopoiesis“

David Steensma, MD

Host: Prof. Dr. Walter Fiedler

Die Veranstaltungen sind mit je **vier Fortbildungspunkten** von der Ärztekammer Hamburg anerkannt.

Speakers



Dr. Paul Richardson is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center and RJ Corman Professor of Medicine at Harvard Medical School and has led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide.

More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates as well as other immunotherapeutic strategies. Furthermore he is leading the development of melflufen, a targeted cytotoxic and a first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein.

He has published extensively, having authored or co-authored over 380 original articles and 300 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is member of several committees and alliances and has received numerous awards for his work.



Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts.

Dr. Brown's research interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has been instrumental in the clinical development of idelalisib and ibrutinib, leading to their

regulatory approvals in CLL. Her genomics work has characterized the somatic mutation profile of CLL, and she also has a longstanding research interest in the inherited predisposition to CLL.

To date she has published about 250 papers in the scientific literature, predominantly in CLL. She is a member of the International Workshop on CLL (iwCLL) and enjoys a worldwide reputation as a CLL expert.



Dr. David Steensma is the Edward P. Evans Chair of MDS Research at the Dana-Farber Cancer Institute (DFCI) in the Division of Hematological Malignancies, Department of Medical Oncology, and Associate Professor of Medicine at Harvard Medical School.

He directs the Center for Prevention of Progression at DFCI for patients with clonal hematopoiesis and other hematological malignancy precursor conditions, and was the founding clinical director of the Regenerative Medicine and Stem Cell Biology course at Harvard Medical School.

Dr. Steensma's clinical and research focus is clonal hematopoiesis and development of novel therapies for myelodysplastic syndromes and marrow failure disorders. He has led a number of multicenter trials and has more than 400 peer-reviewed publications. He is the editor in chief of the ASH Clinical News and has served as a member of the FDA's Oncology Drug Advisory Committee, section editor for Journal of Clinical Oncology, hematology examination committee for the American Board of Internal Medicine, education program chair for the American Society of Hematology (ASH), and senior editor of the ASH Self Assessment Program (ASH-SAP).